Constipation in Emergency Medicine Clinical Presentation

  • Author: Dave A Holson, MD, MBBS, MPH; Chief Editor: Barry E Brenner, MD, PhD, FACEP   more...
 
Updated: Jun 14, 2010
 

History

History is most relevant regarding the etiology of constipation. During the history, clinicians should ask about current medications (including over-the-counter, herbal agents, and prescription medications), history of previous colonoscopy, and any other medical problems. The clinician should also check for the presence of abdominal pain as a primary symptom (if present, irritable bowel syndrome with constipation [IBS-C] should be considered). Understanding the type and degree of disability caused by the symptoms is also important. Disability may include the following:

  • Length of time attempting rectal evacuation
  • Number of bowel movements per week
  • Presence of chronic straining and/or hard stools
  • Use of manual maneuvers to facilitate defecation

The patient may be totally asymptomatic or complain of the following:

  • Abdominal bloating
  • Pain on defecation
  • Rectal bleeding
  • Spurious diarrhea
  • Low back pain

The onset of symptoms is also very important, as intestinal obstruction can present as acute constipation.

The following also suggest that the patient may have difficult rectal evacuation:

  • Feeling of incomplete evacuation
  • Digital extraction
  • Tenesmus
  • Enema retention

However, the following signs and symptoms should be concerning:

  • Rectal bleeding
  • Abdominal pain
  • Inability to pass flatus
  • Vomiting
  • Unexplained weight loss
Next

Physical

General physical examination often is of no benefit in determining etiology or deciding on treatment. The following are exceptional findings:

During the rectal examination, the patient should be assessed for the following:

  • Perianal excoriation
  • Skin tags/hemorrhoids
  • Anal fissure
  • Anocutaneous reflex
  • Prolapse during straining

Digital rectal examination provides information about the following:

  • Anorectal masses
  • Tone of the internal anal sphincter
  • Strength of the external anal sphincter and puborectalis muscle
  • Presence of a rectocele (an outpouching usually present in the anterior rectal wall)
  • Presence of gross blood or occult bleeding by checking the stool guaiac
  • Presence of fecal impactionPseudo-obstruction secondary to fecal impaction. Pseudo-obstruction secondary to fecal impaction.
  • Stool amount and consistency: In pelvic outlet dysfunction, more stool is present in the rectal vault than in colonic inertia or irritable bowel syndrome, in which little or no stool remains in the rectum between defecations. Pelvic floor dysfunction manifests by failure of descent of the examining finger and contraction of the upper segment of the sphincter during straining.
Previous
Next

Causes

The etiology of constipation is usually multifactorial, but it can be divided into 2 main groups: primary constipation and secondary constipation.

Primary constipation

Primary (idiopathic, functional) constipation can generally be classified into 3 categories:

  • Normal-transit constipation (NTC) is the most common subtype of primary constipation. Although the stool is passing through the colon at a normal rate, patients perceive difficulty in evacuating their bowels. Patients in this category sometimes meet the criteria for IBS-C. The primary difference between chronic constipation and IBS-C is the prominence of abdominal pain or discomfort in IBS. Patients with NTC usually have a normal physical examination.
  • Slow-transit constipation (STC) is characterized by infrequent bowel movements, decreased urgency, or straining to defecate. It occurs more commonly in female patients. Patients with STC have impaired phasic colonic motor activity. These patients may demonstrate mild abdominal distention or palpable stool in the sigmoid colon.
  • Pelvic floor dysfunction (ie, pelvic floor dyssynergia) is characterized by dysfunction of the pelvic floor or anal sphincter. Patients often report prolonged or excessive straining, feeling of incomplete evacuation, or the use of perineal or vaginal pressure during defecation to allow the passage of stool or report digital evacuation of stool.

Secondary constipation

Secondary constipation: Several medical conditions and medications may lead to chronic constipation.

  • Diet and exercise - Low-fiber content, decreased fluid intake, decreased exercise, and ignoring the urge to defecate
  • Structural - Anal fissures, thrombosed hemorrhoids, colonic strictures, obstructing tumors, volvulus, and idiopathic megarectum
  • Endocrinopathic and metabolic -Hypercalcemia, hyperparathyroidism, hypokalemia, hypothyroidism, pregnancy, and diabetes mellitus (Constipation is the most common gastrointestinal problem affecting the diabetic population.)
  • Neurologic - Stroke, Hirschsprung disease, Parkinson disease, multiple sclerosis, spinal cord lesion, Chagas disease, and familial dysautonomia
  • Connective-tissue disorders -Scleroderma, amyloidosis, and mixed connective-tissue disease
  • Drugs
    • Antidepressants (cyclic antidepressants, monoamine oxidase inhibitors [MAOIs])
    • Metals (iron, bismuth)
    • Anticholinergics (benztropine, trihexyphenidyl)
    • Opioids (codeine, morphine)
    • Antacids (aluminum, calcium compounds)
    • Calcium channel blockers (verapamil)
    • Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or diclofenac
    • Sympathomimetics (pseudoephedrine)
    • Cholestyramine and stimulant laxatives (long-term use)
    • Antipsychotics
  • Toxicologic -Lead poisoning
  • Psychologic - Depression, anxiety, somatization, and eating disorders
Previous
 
 
Contributor Information and Disclosures
Author

Dave A Holson, MD, MBBS, MPH  Assistant Professor of Emergency Medicine, Mount Sinai School of Medicine; Director, Department of Emergency Medicine, Queens Hospital Center

Dave A Holson, MD, MBBS, MPH is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, National Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

William K Chiang, MD  Associate Professor, Department of Emergency Medicine, New York University School of Medicine; Chief of Service, Department of Emergency Medicine, Bellevue Hospital Center

William K Chiang, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Eugene Hardin, MD, FAAEM, FACEP  Former Chair and Associate Professor, Department of Emergency Medicine, Charles Drew University of Medicine and Science; Former Chair, Department of Emergency Medicine, Martin Luther King Jr/Drew Medical Center

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Barry E Brenner, MD, PhD, FACEP  Professor of Emergency Medicine, Professor of Internal Medicine, Program Director, Emergency Medicine, University Hospitals, Case Medical Center

Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York Academy of Sciences, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

References
  1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. Apr 2006;130(5):1480-91. [Medline].

  2. Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J. Feb 2004;97(2):129-34. [Medline].

  3. Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. Manag Care Interface. Dec 2006;19(12):43-9. [Medline].

  4. Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum. Jan 1989;32(1):1-8. [Medline].

  5. [Guideline] Ternent CA, Bastawrous AL, Morin NA, Ellis CN, Hyman NH, Buie WD. Practice parameters for the evaluation and management of constipation. Dis Colon Rectum. Dec 2007;50(12):2013-22. [Medline]. [Full Text].

  6. Kapoor S. Management of constipation in the elderly: emerging therapeutic strategies. World J Gastroenterol. Sep 7 2008;14(33):5226-7. [Medline]. [Full Text].

  7. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. May 29 2008;358(22):2344-54. [Medline]. [Full Text].

  8. Camilleri M. Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil. Apr 2005;17(2):157-65. [Medline].

  9. Kraft MD. Emerging pharmacologic options for treating postoperative ileus. Am J Health Syst Pharm. Oct 15 2007;64(20 Suppl 13):S13-20. [Medline].

  10. Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol. Feb 2009;296(2):G295-301. [Medline]. [Full Text].

  11. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. Jan 2008;103(1):170-7. [Medline].

  12. Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. Apr 2010;55(4):1090-7. [Medline].

  13. Pharmaceutical Business Review. Ironwood Pharma, Forest Labs Present Linaclotide Phase 3 Trial Results. pharmaceutical-business-review.com. Available at http://clinicaltrials.pharmaceutical-business-review.com/news/ironwood_pharma_forest_labs_present_linaclotide_phase_3_trial_results_100504/. Accessed May 4, 2010.

  14. Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. Mar 2010;138(3):886-95.e1. [Medline].

  15. Johanson JF. Review of the treatment options for chronic constipation. MedGenMed [serial online]. May 2, 2007;9 (2):25-40. Accessed April 26, 2010. Available at http://www.medscape.com/viewarticle/550956.

  16. [Best Evidence] [Guideline] Eoff JC. Optimal treatment of chronic constipation in managed care: review and roundtable discussion. J Manag Care Pharm. Nov 2008;14(9 Suppl A):1-15. [Medline]. [Full Text].

  17. Halligan S, Bartram CI. The radiological investigation of constipation. Clin Radiol. Jul 1995;50(7):429-35. [Medline].

  18. Harari D, Gurwitz JH, Avorn J, Bohn R, Minaker KL. How do older persons define constipation? Implications for therapeutic management. J Gen Intern Med. Jan 1997;12(1):63-6. [Medline]. [Full Text].

  19. Johanson JF, Sonnenberg A, Koch TR. Clinical epidemiology of chronic constipation. J Clin Gastroenterol. Oct 1989;11(5):525-36. [Medline].

  20. Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3(2):357-64. [Medline]. [Full Text].

  21. Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3(2):357-64. [Medline]. [Full Text].

  22. Lembo A, Camilleri M. Chronic constipation. N Engl J Med. Oct 2 2003;349(14):1360-8. [Medline].

  23. Martin H, Slyk MP, Deymann S, Cornacchione MJ. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia. J Am Med Dir Assoc. Jul-Aug 2003;4(4):183-8. [Medline].

  24. Mezwa DG, Feczko PJ, Bosanko C. Radiologic evaluation of constipation and anorectal disorders. Radiol Clin North Am. Nov 1993;31(6):1375-93. [Medline].

  25. Rantis PC Jr, Vernava AM 3rd, Daniel GL, Longo WE. Chronic constipation--is the work-up worth the cost?. Dis Colon Rectum. Mar 1997;40(3):280-6. [Medline].

  26. Schiller LR. New and emerging treatment options for chronic constipation. Rev Gastroenterol Disord. 2004;4 Suppl 2:S43-51. [Medline].

  27. Shafik A. Constipation. Pathogenesis and management. Drugs. Apr 1993;45(4):528-40. [Medline].

  28. Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum. Jan 1989;32(1):1-8. [Medline].

  29. Velio P, Bassotti G. Chronic idiopathic constipation: pathophysiology and treatment. J Clin Gastroenterol. Apr 1996;22(3):190-6. [Medline].

Previous
Next
 
Large amount of stool throughout the colon.
Large stool mass in hepatic flexure of the colon.
Colon distension secondary to fecal impaction.
Pseudo-obstruction secondary to fecal impaction.
Distended transverse colon.
Distended rectum.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.